ð¨ The patent cliff is a catchy headline. But in practice, its often the wrong story.
In pharma, investors are trained to look for a single cliff: patent expiry monopoly ends generic competition floods in revenues drop sharply. That narrative is e…
The real patent is the weak one nobody challenged.
That line hits like a reminder that the most expensive battles in pharma arent always fought on the battlefield everyones watching.
For years, the industry narrative around patent thickets has been fra…
The Blockbuster’s Real Patent Is the Weak One Nobody Challenged Read Post »
Strong IP Doesnt Win in Court. Enforceable IP Does.
Patent owners have been taught a comforting story: write strong claims, keep the paper waterproof, and the courtroom will do the rest. But the real world is harsherand far less forgivingespecially i…
Strong IP Doesn’t Win in Court. Enforceable IP Does. Read Post »
Stop calling it loss of exclusivity for most drugs. Its the loss of pricing powernot revenue.
For years, the industry has described post-patent life as a neat, predictable transition: exclusivity ends, competition enters, revenue inevitably falls. Its …
Drug patent wars arent won in courttheyre won in the archive.
If youve watched (or worked on) drug patent litigation, youve probably noticed a pattern: the loudest legal firepower doesnt always translate into the fastest wins. What consistently separat…
The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation Read Post »
Most drug patent fights are decided before the courtroom ever opens.
In theory, the legal system rewards right. In practice, drug patent litigation is often won by the side that did the better work product first: better prior art searching, better clai…
The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation Read Post »
The quiet strategy that can beat a patent cliff isnt always a lawsuitits timing.
For years, patent cliff talk has sounded like a countdown clock: the last day a brand has market exclusivity, then generic entry arrives and margins evaporate.
But the rea…
The Authorized Generic That Beats the Patent Cliff to Market Read Post »
Most pharma portfolios dont have a patent problem. They have a timing problem.
The gap between a genuinely defensible, litigation-ready drug patent and a later, already-listed patent can be wider than many companiesespecially those that model value usi…
One Day Late. Nine Figures Short. What First to File Really Costs.
If you ever needed a reminder that patent law is less about inspiration and more about timing, look no further than the cautionary tale at the heart of first to file.
In pharmaand e…
One Day Late, Nine Figures Short: What Being the Second First-to-File Actually Costs Read Post »
One day late. Nine figures short.
Thats the headline lesson from a recent patent dispute in the pharmaceutical worldone where timing wasnt just important, it was existential. In a market built on years of R&D, regulatory timelines, and blockbuster …
One Day Late, Nine Figures Short: What Being the Second First-to-File Actually Costs Read Post »
Get new actionable insights and updates from BiotechBlog
